title: Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxemia.
abstract: Bactericidal/permeability-increasing protein (BPI), a cationic protein isolated from human neutrophils, binds lipopolysaccharide (LPS), kills gram-negative bacteria, and neutralizes many of the effects of LPS in vitro and in vivo. We hypothesized that a recombinant 23-kDa NH2-terminal fragment of BPI (BPI23) would reduce acute lung injury in endotoxemic pigs. At -18 h, pigs received an intravenous priming dose of LPS (20 micrograms/kg). Anesthetized ventilated swine were randomized to receive 1) no further treatment (n = 4); 2) LPS (250 micrograms/kg over 50 min) and BPI23 (3-mg/kg bolus and 3 mg/kg over 60 min) (n = 6); or 3) LPS and thaumatin, a cationic protein devoid of LPS neutralizing activity that has a molecular mass and isoelectric point that are similar to that of BPI23 (n = 7). BPI23 treatment significantly ameliorated LPS-induced hypoxemia, functional upregulation of opsonin receptors on circulating phagocytes, and alveolitis but had no effect on the elaboration of tumor necrosis factor-alpha or thromboxane A2. The salutory effects of BPI23 on acute lung injury in endotoxemic pigs may be mediated, at least in part, by inhibition of direct activation of phagocytes by LPS.
authors.affiliation: Department of Surgery, Massachusetts General Hospital, Boston 02114.
authors.forename: T J
authors.initials: TJ
authors.lastname: Vandermeer
authors.forename: M J
authors.initials: MJ
authors.lastname: Menconi
authors.forename: B P
authors.initials: BP
authors.lastname: O'Sullivan
authors.forename: V A
authors.initials: VA
authors.lastname: Larkin
authors.forename: H
authors.initials: H
authors.lastname: Wang
authors.forename: R L
authors.initials: RL
authors.lastname: Kradin
authors.forename: M P
authors.initials: MP
authors.lastname: Fink
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000502:physiology; D001798:Blood Proteins / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015777:Eicosanoids / Q000096:biosynthesis; D004926:Escherichia coli / Q000378:metabolism; D008070:Lipopolysaccharides; D008170:Lung Compliance / Q000502:physiology; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008565:Membrane Proteins; D009895:Opsonin Proteins / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D010587:Phagocytosis; D013552:Swine; D014115:Toxemia / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; D015777:Eicosanoids; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D009895:Opsonin Proteins; C021623:bactericidal permeability increasing protein; D009195:Peroxidase